Structure Therapeutics Inc To Host Investor Call Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Evan Seigerman - BMO Capital Markets - Analyst : Congrats on the progress. So I see you noted that 2671 is GSH negative in vitro but given some recent failures of other assays and development in the obesity space, can you walk me through your confidence in this assay that you won't have any downstream liver toxicity and say if liver tox were to emerge kind of in your GLP studies, how long till you think you would see that and how could you pivot?

Question: Terence Flynn - Morgan Stanley - Analyst : Two part for me. Just wondering based on the structure of the molecule, if you foresee any potential DDI issues at this point, not just with oral GLP-1s, but any other classes of drugs that patients might get in this setting. And then the second part of the question is when we ultimately get full data for Novo's CagriSema, just curious what you'll be most interested to see there aside from the efficacy and safety data.

Question: Seamus Fernandez - Guggenheim Partners - Analyst : So just a couple in terms of the actual profile of the molecule as it relates to half-life and what you see as the kind of ideal amylin agonist relative to GLP-1s. We've talked about Cmax with GLP-1s. What do we know about sort of approaching the amylin receptor in terms of the sort of ideal Cmax versus kind of saturating the receptor. Maybe you can just kind of help us understand what your expected ideal half-life would be for this compound and what -- given what we know of the amylin receptor and how it operates, how tolerability and efficacy may trade off with the profile of a small molecule?

Question: Yasmeen Rahimi - Piper Sandler Companies - Analyst : Thank you so much for the great update and congrats on this great development. I guess the first question is how should we be thinking about sort of your strategy in being in the clinic? Like could you be able to -- is your thought to get the IND cleared and start these studies in the US? Is the thought to potentially maybe start the studies outside of the US while you're filing the IND? Could we be contemplating sort of like if we have first-in-human start? Like where would you be in talks fast forward next December by now? And I feel like I've definitely used up more than one question. So I will get back in the queue without pissing off my former colleagues. Yeah.

Question: Roger Song - Jefferies Group - Analyst : And my congratulations to the amylin program selection DC. So I have a question related to the efficacy. And understanding you shared with us the weight loss at the day 23, just curious about the weight loss trajectory. Do you see onset mean versus the maximum weight loss and then how we think about the maintenance of the weight loss after 28 days dosing? Just curious about the trajectory. If you can share with us a little bit more.

Question: Kevin Strang - Goldman Sachs - Analyst : This is Kevin on for Chris and just wanted to add my congratulations as well. I just had a question on the prioritization of the development of DACRA assay versus the selective amylin receptor agonist. I know you mentioned cagri obviously as a comp there, but anything else that you could say on that? And then in terms of moving forward and bringing forward more assays, how do you prioritize that over the next couple of years given potential to bring forward another amylin assay or GIPR, et cetera?

Question: Hardik Parikh - JPMorgan Chase - Analyst : I had just a couple on I saw that you're expecting data on this program by year end 2026 and I was just wondering in the meantime, in the next kind of couple of years, what kind of data or updates can we expect from this program from you guys before the end of the trial? And then you mentioned that in Phase 2, you'll explore as both monotherapy and combo with GLP-1s. Any thought on testing with any other incretin and is there a possibility you could test in combo in Phase 1 as well?

Question: Jonathan Wolleben - JMP Securities - Analyst : Ray, just piggybacking off that last comment, what do we know about amylin's ability to preserve lean mass when it combines with a GLP? And it sounds like 2671 and 1290 could play well together. Is your expectation that this could be formulated into a single pill eventually?

Question: Dennis Kennedy - LifeSci Capital - Analyst : This is Dennis on for Myriam. Thanks so much for taking our question and congrats on the candidate nomination. We hear that amylin agonist is maybe more tolerable because it induces satiety, which is maybe slightly different from the way that GLP-1s prevent hunger. Just curious if you had any thoughts on the satiety induced with amylin and if this is what's really making the difference in tolerability. Is there any good way to kind of measure satiety in a clinical trial and is that something you'll be looking at?

Question: Prakhar Agrawal - Cantor Fitzgerald - Analyst : Maybe a couple of preclinical. What's the selectivity of this candidate, 261 for -- 2671 for the dimer specifically, which dimer does it bind to amongst RAMP 1, 2, 3 plus calcitonin as well as your confidence on avoiding binding to other GPCR complexes. And I think in this preclinical slides, it's mentioned tolerability up to 300 mgs per kg in rat. Did you see any additional tox in larger animals such as dog? And on the clinical side, you've talked about taking multiple amylin candidates into the clinic. Could the Phase 1 trial that will be initiated have the option to include everything -- include multiple amylin candidates? I'm just trying to understand what's the optimized path to find the right candidate.